Frontlight ResearchEarly access
Dermatomyositis and polymyositis (myositis) trials in United States
34 of 45 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleRESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Where
- Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Chapel Hill, Chicago, Dallas, Durham, Houston, Jacksonville, Kansas City, Milwaukee, Nashville, New York, Orange, Philadelphia, Pittsburgh, Portland, Rochester, Salt Lake City, San Francisco, Seattle, St. Petersburg, The Bronx
- Age
- 6 years to 75 years
- People
- 74 worldwide
- Run by
- Cabaletta Bio
See details and how to joinNCT06154252 · EU 2025-521145-24-01 - Phase 2Taking peopleUblituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- Where
- Atlanta, Baltimore, Birmingham, Chicago, Great Neck, Houston, Pittsburgh, Rochester
- Age
- 18 years and over
- People
- 30
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT07103746 - Phase 2Taking peopleFAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
- Where
- Bethesda
- Age
- 18 years to 62 years
- People
- 3,000
- Run by
- National Institute of Environmental Health Sciences (NIEHS)
See details and how to joinNCT07111065 - Phase 3Not yet taking people in United StatesA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Ann Arbor, Aurora, Baltimore, Boston, Chicago, Cleveland, Dallas, Fairway, Great Neck, Hershey, Houston, Irvine, Jackson, Los Angeles, Middleburg Heights, Philadelphia, Pittsburgh, Portland, Rochester, San Francisco, Scottsdale, St Louis
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - Phase 1Taking peopleTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Where
- Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03816345 - Phase 1/2Taking peopleA Study of AZD0120 in Autoimmune Diseases
- Where
- Ann Arbor, Baltimore, Chapel Hill, Chicago, Duarte, Miami, New York, Seattle, Stanford, St Louis, Tucson
- Age
- 18 years to 75 years
- People
- 27 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07295847 - Phase 1Taking peopleA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Where
- Aurora, Baltimore, Charleston, Charlotte, Chicago, Durham, East Brunswick, Greenville, Iowa City, Jacksonville, Kansas City, Loma Linda, Louisville, New York, Phoenix, Salt Lake City, Valhalla
- Age
- 18 years to 74 years
- People
- 66 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT07085104 - Phase 1/2Taking peopleA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Where
- Ann Arbor, Charlotte, Dallas, Fairway, Hackensack, Los Angeles, Minneapolis, New York, Plantation, Summit, Syracuse, Tampa
- Age
- 18 years to 75 years
- People
- 240
- Run by
- Nkarta, Inc.
See details and how to joinNCT06733935 - Phase 2Taking peopleTopical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
- Where
- Cleveland
- Age
- 18 years to 89 years
- People
- 15
- Run by
- The Cleveland Clinic
See details and how to joinNCT06857240 - Phase 1Taking peopleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Where
- Boston, Chapel Hill, Chicago, Iowa City, La Jolla, New Orleans, Portland, Redwood City, St Louis
- Age
- 18 years to 70 years
- People
- 80 worldwide
- Run by
- CRISPR Therapeutics
See details and how to joinNCT06925542 - Phase 1Taking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Anniston, Birmingham, Chapel Hill, Iowa City, La Jolla, Omaha, Sacramento
- Age
- 18 years to 70 years
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - Phase 3Enrolling by invitationA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- Atlanta, Austin, Baltimore, Beverly Hills, Chapel Hill, Chicago, Columbus, Gainesville, Great Neck, Houston, Jacksonville, New Haven, Orange, Phoenix, Pittsburgh, Portland, San Francisco, Tampa
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - Phase 1Not yet taking people in United StatesA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, Worcester
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - Phase 1Enrolling by invitationA Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Where
- Duarte, New York, Stanford, Tampa
- Age
- 18 years and over
- People
- 52 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07038447 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Allen, Amarillo, Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Beckley, Boca Raton, Boston, Boynton Beach, Charleston, Charlotte, Cleveland, Colleyville, Denver, Durham, El Paso, Fairway, Gainesville, Galveston, Great Neck, Harlingen, Houston, Irvine, Margate, Miami, Middleburg Heights, Milwaukee, New Haven, North Richland Hills, Orlando, Palm Beach Gardens, Philadelphia, Phoenix, Pittsburgh, Plant City, Sterling Heights, Summerville, Washington D.C., Willowbrook
- Age
- 18 years to 75 years
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - Phase 3Taking peopleA Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Where
- Beckley, Boston, Cleveland, Edinburg, Frisco, Glendale, Harlingen, Houston, Jacksonville, Katy, Los Angeles, Margate, Miami, New York, Oklahoma City, Orange, Orlando, Phoenix, Pittsburgh, Plantation, Rancho Mirage, Scottsdale, St Louis, Tamarac, Weslaco
- Age
- 18 years and over
- People
- 318 worldwide
- Run by
- Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00 - Phase 1/2Taking peopleFT839 in Autoimmune Diseases
- Where
- Fullerton
- Age
- 18 years to 70 years
- People
- 446
- Run by
- Fate Therapeutics
See details and how to joinNCT07800871 - Phase 3Taking peopleA Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- Where
- Beckley, Frisco, Glendale, Houston
- Age
- 18 years and over
- People
- 211 worldwide
- Run by
- Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00 - Phase 2Taking peopleEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
- Where
- Miami
- Age
- 18 years and over
- People
- 5
- Run by
- University of Miami
See details and how to joinNCT07486869 - Phase 2Taking peopleDescartes-08 in Autoantibody Myositis
- Where
- Austin, Boston, Chapel Hill, Orange
- Age
- 18 years and over
- People
- 60
- Run by
- Cartesian Therapeutics
See details and how to joinNCT07391605 - Phase 2Taking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Arlington, Bellaire, Charleston, Charlotte, Chula Vista, Covina, Gainesville, Great Falls, Hixson, Iowa City, Irving, Jackson, Jupiter, Katy, Los Alamitos, Los Angeles, Mesquite, Miami, Norcross, Phoenix, Plantation, Red Oak, Roanoke, Santa Ana, Statesville, Tucson, Tuscaloosa, Tustin, Willowbrook, Woodland
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - Phase 1Not yet taking people in United StatesBAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
- Where
- Boston
- Age
- 16 years to 75 years
- People
- 94
- Run by
- Luminary Therapeutics
See details and how to joinNCT07729995 - Phase 1/2Taking peopleDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
- Where
- Cincinnati, St Louis, Washington D.C.
- Age
- 12 years and over
- People
- 50
- Run by
- Cartesian Therapeutics
See details and how to joinNCT07089121 - Phase 1Taking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Amarillo, Austin, Baltimore, Chapel Hill, Columbus, Houston, Lake Success, New York, Orange, Philadelphia, Portland
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - Phase 1Taking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Boston, Durham
- Age
- 18 years and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00